Renowned Speakers

Mila Jakovljevic

Polyclinic for Cardiova Polyclinic for Cardiovascular Diseases and Prevention Croatia Croatia

jeko madjarov

Carolinas Healthcare System Pineville USA USA

jacob astrowsky

Rainbow Babies & Children’s Hospital USA USA

Aris Lacis

Children’s Clinical University Hospital Latvia Latvia

Wenhua Ling

Sun Yat-Sen University China China

Marc-Alexander Ohlow

Zentralklinik Bad Berka Germany Germany

Mark Caulfield

William Harvey Research Institute & Queen Mary University of London UK UK

Damien Byas

Center for Healthcare and Organizational Research, USA USA USA

Recommended Global Cardiology Webinars & Conferences

Europe & UK

Asia Pacific & Middle East

Canada

heart conference 2022

About conference

Conference Series llc Ltd is inviting all participants across the globe to attend 7th International Conference on Clinical Cardiology & Congenital Heart Diseases on May 30-31, 2022, Yokohama, Japan. This Cardiology Conference will bring together world-class professors, scientists and cardiologists to discuss Clinical Cardiolog y, cardio vascular, cardio Auscultation, cardiac nursing , cardiac Toxicity, heart sounds, Cardiology, Cardiovascular Surgery, Hypertension and Health care, cardiology patients simulator, carotid arteries , Cardiac Pharmacology, developmental origins of health & diseases, cardiovascular safely trail, cardiomyoplasty, cardiac mapping, Nutrition, Diet & Exercise, Cardiac and Cardiovascular Research, Heart Devices and Diabetes, Obesity & Stroke.

HEART CONFERENCE 2022 is designed to provide diverse and current education that will keep cardiology professionals a breast of the issues affecting the prevention, diagnosis and treatment of cardiovascular disease. The conference will be organized around the theme " Intermediate and Long-Term Impact of COVID-19 on Cardiovascular Disease”.

HEART CONFERENCE 2022 aims to provide an opportunity to share knowledge, expertise along with unparalleled networking opportunities between a large number of medical professionals like Directors, Heads, Deans, Professors, Scientists, Researchers, Cardiologists, Founders and Employees of the related companies, Associations, Organizations, Laboratory members and Young researchers working in the field of Cardiology & Heart treatment. This Cardiology conference mainly focuses on spreading the awareness about challenges in this fields and how to prevent and manage the techniques of Cardiac Imaging, Cardiology and Cardiac nursing.

Conference Series llc Ltd. Organizes 300+ conferences, 500+workshops and 200+symposiums on Clinical, Medicine, Nursing, cardiology diagnosis workshops, cardiac nursing conferences, Cardiology Conferences ,Heart conferences and Science & Technology every year across USA, Europe, Asia, Middle East, Australia and UK with support from 1000 more scientific societies and Publishes 500 open access journals which contains over 30000 eminent personalities, reputed scientists as editorial board members.

Why to attend??

Encounter the target market with members from across the globe, committed to learn about Cardiology techniques. This is the best opportunity to outreach the largest gathering of participants from around the world. Conduct presentations, distribute and update knowledge about the current situation of nuclear cardiology & echocardiography technique and receive name recognition at this 2-days event. World-eminent speakers, most recent researches, latest treatment techniques and the advanced updates in Nuclear Cardiology are the principal features of Cardiology Conferences

Target Audience:

Our Organization would be privileged to welcome the:

Directors of Cardiology and related Programs or Associations

Heads, Deans and Professors of Cardiology and related departments

Scientists and Researchers

Cardiology Associations and Organizations

Laboratory members and Students working in the field of Cardiology.

Sessions and Tracks

Track 1: Heart Diseases

Heart disease is identified by destruction in one of the four heart valves: the mitral, aortic, tricuspid or pulmonary. The mitral and tricuspid valves control the flow of blood between the atria and the ventricles (the upper and lower chambers of the heart). The pulmonary valve controls the blood flow from the heart to the lungs, and the aortic valve governs blood flow between the heart and the aorta, and thereby the blood vessels to the rest of the body. The mitral and aortic valves are the ones most frequently affected by valvular heart disease.

Related Cardiology Conferences: 5th World Congress on Cardiology and Cardiovascular Therapeutics, August 12-13, 2021 webinar | Asian Global Summit on Heart and Emergency Medicine, November 01-02, 2021 webinar | International Conference on Hypertension and lifestyle disorders, November 25-26, 2021 webinar | International Conference on, Cardiology and Heart Failure, December 02-03, 2021 webinar |27th International Conference & Exhibition on, Cardiology and Cardiovascular Medicine, July 26-27, 2021 webinar

Major Cardiology Societies / Associations:

Track 2: Heart Regeneration

The human heart is continually operating as a muscular pump, contracting, on average, 80 times per minute to propel 8000 liters of blood through body tissues each day. Whereas damaged skeletal muscle has a profound capacity to regenerate, heart muscle, at least in mammals, has poor regenerative potential. This deficiency is attributable to the lack of resident cardiac stem cells, combined with roadblocks that limit adult cardiomyocytes from entering the cell cycle and completing division. Insights for regeneration have recently emerged from studies of animals with an elevated innate capacity for regeneration, the innovation of stem cell and reprogramming technologies, and a clearer understanding of the cardiomyocyte genetic program and key extrinsic signals. Methods to augment heart regeneration now have potential to counteract the high morbidity and mortality of cardiovascular disease.

Major Cardiology Societies / Associations:

Track 3: Track 3: Cardiomyopathy and Heart Failure

Cardiomyopathy, also called dilated cardiomyopathy, the heart becomes expanded and weakened and inadequate to pump effectively. The many causes of heart failure is cardiomyopathy. Heart failure occurs when the heart does not pump strongly enough to meet the needs of the body. If the heart doesn't pump with the force needed, the body's tissues will not get enough oxygen. Heart failure develops gently as the heart muscle weakens. If the right side of the heart is affected, the heart is unable to pump adequate blood to the lungs to be oxygenated. If the left side of the heart is affected, it is unable to pump enough blood to the rest of the body. In most cases, heart failure affects both left and right side, but it can occur on just one side.

Major Cardiology Societies / Associations:

Track 4: Coronary heart diseases (CAD)

Coronary artery disease (CAD), also known as ischemic heart disease. Coronary heart disease is a common term for the buildup of plaque in the heart’s arteries that could lead to heart attack. With coronary artery disease, plaque first grows within the walls of the coronary arteries until the blood flow to the heart’s muscle is limited. It may be chronic, narrowing of the coronary artery over time and limiting of the blood supply to part of the muscle. Or it can be acute, resulting from a sudden rupture of a plaque and formation of a thrombus or blood clot. A common symptom is chest pain or discomfort which may travel into the shoulder, arm, back, neck, or jaw.

· Arrhythmia

· Atherosclerosis

· Congenital heart defects

Major Cardiology Societies / Associations:

Track 5: Cardiovascular Surgeries

Cardiovascular (heart) surgery is surgery on the heart or great vessels performed by cardiac surgeons. Frequently, it is done to treat complications of ischemic heart disease, correct congenital heart disease, or treat valvular heart disease from various causes including endocarditis, rheumatic heart disease and atherosclerosis.

Major Cardiology Societies / Associations:

Track 6: Obesity & Stroke

Obesity can increase the risk of stroke due to inflammation caused by excess fatty tissue. This can lead to difficulty in blood flow and an increased risk of blockage, both of which can cause strokes. It's also a major cause of gallstones, osteoarthritis and respiratory problems. Having diabetes or pre-diabetes puts one at increased risk for heart disease and stroke. One can lower its risk by keeping the blood glucose (also called blood sugar), hypertension, and blood cholesterol close to the recommended target numbers the levels suggested by diabetes experts for good health. Two of the best ways to lower your risk of stroke are by eating a heart healthy diet with plenty of fruits and vegetables, eating sensible portions and being physically active on a regular basis.

Major Cardiology Societies / Associations:

Track 7: Cardiometabolic Health and Diabetes

Cardio metabolic disorders are assemblage of health circumstances associated with cardiovascular disease and diabetes. The morbidity and mortality severity increased clinical attention to address risk factors predisposing individuals to these cardiovascular disorders. Diabetes affects this vital function as prolonged, poorly controlled blood glucose levels increase the risk of the body's blood vessels narrowing or becoming blocked. The medical conditions and their related risk-factors can control the complications by evidence-based treatments while improving health literacy.

Major Cardiology Societies / Associations:

Track 8: Pediatric Cardiology

Pediatric Cardiology plays a major role in the diagnosis of congenital heart defects, performing diagnostic procedures such as echocardiograms, cardiac catheterizations, and for the ongoing management of the sequel of heart disease in infants, children and adolescents. In childhood, a disorder which involves both the heart and lungs problems, called Pediatric Cardiopulmonary disease. Epicardia adipose tissue (EAT) is the visceral fat deposit over the heart and is often increased in obese subjects. EAT is connected to Cardio Metabolic risk factors and non-alcoholic fatty liver disease (NAFLD) in adults, but this relationship is not well known in children. (MI) Myocardial infarction is rare in childhood and adolescence. Nursing and care for pediatric cardiac patients also plays an important role for the cure of pediatric cardiac patients. The discussion about the widespread problem of the baby heart diseases as Myocarditis, Hypertension, Cardiomyopathy, Heart Murmur, Hypo plastic Left Heart Syndrome, Pericarditis Effusion, Cardiac Arrest, Arrhythmogenic Right Ventricular Dysplasia, Cyanotic Heart Disease, and Pediatric Arrhythmia.

Major Cardiology Societies / Associations:

Track 9: Cardiac Nursing

Cardiovascular nursing is a specialty that works with patients who suffer from numerous conditions of the cardiovascular system. Cardiac nurses, also called cardiovascular nurses or cardiology nurses, are registered nurses (RNs) who have specialized in the cardiovascular system. They work with patients who have heart problems by following the treatment plan a cardiologist assigns, monitoring patient progress and administering medication to help the healing process.

Cardiovascular nurses facilitate treat conditions like unstable angina, myocardial infarction, cardiomyopathy, coronary artery disease, cardiac dysrhythmia and congestive heart failure under the direction of a heart specialist (cardiologist). Cardiovascular nurses perform postoperative care on a stress test evaluation, cardiac monitoring, surgical unit, health assessments and vascular monitoring. Cardiovascular nurses must possess specialized skills including defibrillation, electrocardiogram monitoring and medication administration by continuous intravenous drip.

Major Cardiology Societies / Associations:

Track 10: Cardiac Pharmacology

Cardiovascular pharmacology deals with the medication of cardiac diseases. Cardiac Pharmacology is for patients with cardiac diseases, and the different drugs associated with cardiovascular therapies. The Cardiac Drugs are used to treat conditions of the heart or the circulatory or vascular system. Many classes of cardiovascular agents are available to treat the various cardiovascular conditions. In this sub topic we have Sodium, potassium, calcium channel blockers, ACE-inhibitors and Cardiac biomarkers. There are many types of cardiovascular drugs in the market that include Cardiac glycosides, antiarrhythmic agents, antianginal agents and antihypertensive agents.

Major Cardiology Societies / Associations:

Track 11: Clinical Trials in Cardiology

Clinical trials are research-oriented study that investigates whether a medical methodology or device is safe for use and effective for humans being. These studies will show that medical approaches work best for certain diseases or groups of individuals. The available Clinical trials produce data is best for health care decision making. A clinical trial will help to find a new strategy, treatment or device. There are four possible outcomes from a clinical trial. Positive trial, Non-inferior trial, Inconclusive trial, Negative trial.

Major Cardiology Societies / Associations:

Track 12: Women & Heart Disease

Although heart disease may often be thought of as a problem for men, heart disease is the most common cause of death for both women and men. One challenge is that some heart disease symptoms in women may be different from those in men. Fortunately, women can take steps to understand their unique symptoms of heart disease and to begin to reduce their risk of heart disease. The most common heart attack symptom in women is some type of pain, pressure or discomfort in the chest. But it is not always severe or even the most prominent symptom, particularly in women. And, sometimes, women may have a heart attack without chest pain.

Major Cardiology Societies / Associations:

Market analysis

Top five drivers of cardiovascular market growth

Total sales for cardiovascular diseases will grow steadily over the next six years, reaching about $60B in 2023. The top five major drivers of this growth will be two anticoagulants (Bristol-Myers Squibb’s [BMS’] Eliquis [apixaban] and Johnson & Johnson [J&J]/Bayer’s Xarelto [rivaroxaban]), a heart failure drug (Novartis’s Entresto [sacubitril/valsartan]) and two drugs for pulmonary arterial hypertension (J&J’s Opsumit [macitentan] and Uptravi [selexipag]). These five drugs will represent 50% of the total cardiovascular market in 2023, while Eliquis and Xarelto alone will represent 36% of the whole cardiovascular market. Cholesterol-lowering drugs were not part of this analysis, as they were considered to be part of the metabolic disorders therapeutic area.

Governments are trying to limit hospital readmissions to reduce the prevalence of hospital acquired infections (HAIs) by imposing penalties on hospitals. As a result, adoption of home healthcare, remote patient monitoring, and long term care services is rapidly increasing. Thus, demand for cardiovascular devices is increasing from hospitals, patients based in home settings, and long term care centers. In addition, favorable government policies such as reimbursement coverage are fueling adoption of these devices. Thus, increasing target patient population, rising acceptance of home healthcare, and favorable government policies are some of the major factors driving the growth of the global cardiovascular devices market.

On the other hand, high device cost and stringent regulatory approval procedure are some of the prime factors challenging the growth of the market. In addition, lack of skilled professionals to perform surgical procedures using advanced devices is impeding the adoption of new devices. The global cardiac monitoring market is expected to register a CAGR of around 4%. North America accounted for the highest market value in 2017. However, Middle East & Africa is expected to register the highest CAGR during the forecast period. Cardiovascular diseases have become one of the primary reasons for mortality and are becoming a major concern in most parts of the world. Coronary heart disease (CHD) is the most common type of heart disease, with a death toll of more than 370,000 people annually. The American Heart Association (AHA) reports cardiovascular disease to be the leading global cause of death, accounting for 17.3 million deaths per year, a number that is expected to grow to more than 23.6 million by 2030. The Heart Foundation also states that CVD is a major cause of death in Australia, with 45,053 deaths attributed to CVD in the country, in 2014.

Segment 1: ECG Systems| Segment 2: Hoter Monitors Segment

3: Implantable Loop Recorders| Segment 4: Others

To Collaborate Scientific Professionals around the World

Conference Date May 30-31, 2022

For Sponsors & Exhibitors

sponsor@conferenceseries.com

Speaker Opportunity

Poster Opportunity E-Poster Opportunity

Useful Links

Past Conference Report

heart conference 2021 Conference

Supported By

Cardiovascular Pharmacology: Open Access Clinical & Experimental Cardiology Journal of Cardiovascular Medicine and Therapeutics

All accepted abstracts will be published in respective Conference Series International Journals.

Abstracts will be provided with Digital Object Identifier by

Clinical Cardiology & Congenital Heart Diseases

May 30-31, 2022 Yokohama, Japan

Intermediate and Long-Term Impact of COVID-19 on Cardiovascular Disease

Conference Series Conferences gaining more Readers and Visitors

Renowned Speakers

Mila Jakovljevic

jeko madjarov

jacob astrowsky

Aris Lacis

Wenhua Ling

Marc-Alexander Ohlow

Mark Caulfield

Damien Byas

Recommended Global Cardiology Webinars & Conferences

Europe & UK

Asia Pacific & Middle East

Canada

heart conference 2022

About conference

Sessions and Tracks

Market analysis

To Collaborate Scientific Professionals around the World

Useful Links

Past Conference Report

Supported By